Effects of human C-reactive protein on pathogenesis of features of the metabolic syndrome

Hypertension

Volumn 57, Issue 4, 2011, Pages 731-737

  Pravenec, Michal ^a   Kajiya, Takashi ^b   Zídek, Václav ^a   Landa, Vladimír ^a   Mlejnek, Petr ^a   Šimáková, Miroslava ^a   Šilhavý, Jan ^a,c   Malínská, Hana ^d   Oliyarnyk, Olena ^d   Kazdová, Ludmila ^d   Fan, Jianglin ^e   Wang, Jiaming ^b   Kurtz, Theodore W ^b  

^a INSTITUTE OF PHYSIOLOGY   (Czech Republic)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c CZECH UNIVERSITY OF LIFE SCIENCES PRAGUE   (Czech Republic)

^d INSTITUTE FOR CLINICAL AND EXPERIMENTAL MEDICINE   (Czech Republic)

^e UNIVERSITY OF YAMANASHI   (Japan)

Author keywords

C reactive protein; metabolic syndrome; oxidative stress; spontaneously hypertensive rat; transgenic

Indexed keywords

ADIPONECTIN; ALANINE AMINOTRANSFERASE; ALBUMIN; APOLIPOPROTEIN E; ASPARTATE AMINOTRANSFERASE; C REACTIVE PROTEIN; CREATININE; CYCLIC GMP; FATTY ACID; GLUCOSE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INSULIN; INTERLEUKIN 6; THIOBARBITURIC ACID REACTIVE SUBSTANCE; TRIACYLGLYCEROL; TUMOR NECROSIS FACTOR ALPHA;

ARTICLE; BLOOD LEVEL; BLOOD PRESSURE; BODY WEIGHT; CLINICAL FEATURE; DIASTOLIC BLOOD PRESSURE; GENE EXPRESSION; GLUCOSE METABOLISM; GLYCOGEN SYNTHESIS; HUMAN; HYPERINSULINEMIA; HYPERTRIGLYCERIDEMIA; INFLAMMATION; INSULIN RESISTANCE; KIDNEY; LIPID METABOLISM; LIVER; METABOLIC SYNDROME X; MICROALBUMINURIA; ORAL GLUCOSE TOLERANCE TEST; OXIDATIVE STRESS; PHENOTYPE; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN EXPRESSION; SKELETAL MUSCLE; SPONTANEOUSLY HYPERTENSIVE RAT; SYSTOLIC BLOOD PRESSURE; TRANSGENE; TRANSGENIC RAT;

ADIPONECTIN; ANALYSIS OF VARIANCE; ANIMALS; BLOOD GLUCOSE; BLOOD PRESSURE; C-REACTIVE PROTEIN; GLUCOSE TOLERANCE TEST; HUMANS; INSULIN; METABOLIC SYNDROME X; OXIDATIVE STRESS; RATS; RATS, INBRED SHR; RATS, TRANSGENIC; TELEMETRY;

EID: 79953225532     PISSN: 0194911X     EISSN: 15244563     Source Type: Journal    
DOI: 10.1161/HYPERTENSIONAHA.110.164350     Document Type: Article

References (31)

1. Ridker PM, Danielson E, Fonseca FA, Genest J, Gotto AM Jr, Kastelein JJ, Koenig W, Libby P, Lorenzatti AJ, Macfadyen JG, Nordestgaard BG, Shepherd J, Willerson JT, Glynn RJ, for the JUPITER Trial Study Group. Reduction in C-reactive protein and LDL cholesterol and cardiovascular event rates after initiation of rosuvastatin: a prospective study of the JUPITER Trial. Lancet. 2009;373:1175-1182.
2. Lavie CJ, Milani RV, Verma A, O'Keefe JH. C-reactive protein and cardiovascular diseases: is it ready for primetime? Am J Med Sci. 2009; 338:486-492.
3. Scirica BM, Morrow DA. Is C-reactive protein an innocent bystander or proatherogenic culprit? The verdict is still out. Circulation. 2006;113: 2128-2134.
4. Ndumele CE, Pradhan AD, Ridker PM. Interrelationships between inflammation, C-reactive protein, and insulin resistance. J Cardiometab Syndr. 2006;1:190-196.
5. Haffner SM. The metabolic syndrome: inflammation, diabetes mellitus, and cardiovascular disease. Am J Cardiol. 2006;97:3A-11A. (Pubitemid 43139714)
6. Elliott P, Chambers JC, Zhang W, Clarke R, Hopewell JC, Peden JF, Erdmann J, Braund P, Engert JC, Bennett D, Coin L, Ashby D, Tzoulaki I, Brown IJ, Mt-Isa S, McCarthy MI, Peltonen L, Freimer NB, Farrall M, Ruokonen A, Hamsten A, Lim N, Froguel P, Waterworth DM, Vollenweider P, Waeber G, Jarvelin MR, Mooser V, Scott J, Hall AS, Schunkert H, Anand SS, Collins R, Samani NJ, Watkins H, Kooner JS. Genetic loci associated with C-reactive protein levels and risk of coronary heart disease. JAMA. 2009;302:37-48.
7. Nordestgaard BG, Zacho J. Lipids, atherosclerosis and CVD risk: is CRP an innocent bystander? Nutr Metab Cardiovasc Dis. 2009;19:521-524.
8. Koike T, Kitajima S, Yu Y, Nishijima K, Zhang J, Ozaki Y, Morimoto M, Watanabe T, Bhakdi S, Asada Y, Chen YE, Fan J. Human C-reactive protein does not promote atherosclerosis in transgenic rabbits. Circulation. 2009; 120:2088-2094.
9. Contois JH, Hartigan C, Rao LV, Snyder LM, Thompson MJ. Analytical validation of an HPLC assay for urinary albumin. Clin Chim Acta. 2006;367:150-155.
10. Malínská H, Oliyarnyk O, Hubová M, Zídek V, Landa V, Simáková M, Mlejnek P, Kazdová L, Kurtz TW, Pravenec M. Increased liver oxidative stress and altered PUFA metabolism precede development of nonalcoholic steatohepatitis in SREBP-1a transgenic spontaneously hypertensive rats with genetic predisposition to hepatic steatosis. Mol Cell Biochem. 2010;335:119-125.
11. de Beer FC, Baltz ML, Munn EA, Feinstein A, Taylor J, Bruton C, Clamp JR, Pepys MB. Isolation and characterization of C-reactive protein and serum amyloid P component in the rat. Immunology. 1982;45:55-70. (Pubitemid 12251007)
12. Devaraj S, Dasu MR, Singh U, Rao LV, Jialal I. C-reactive protein stimulates superoxide anion release and tissue factor activity in vivo. Atherosclerosis. 2009;203:67-74.
13. Zeller JM, Sullivan BL. C-reactive protein selectively enhances the intracellular generation of reactive oxygen products by IgG-stimulated monocytes and neutrophils. J Leukoc Biol. 1992;52:449-455.
14. Zhang R, Zhang YY, Huang XR, Wu Y, Chung AC, Wu EX, Szalai AJ, Wong BC, Lau CP, Lan HY. C-reactive protein promotes cardiac fibrosis and inflammation in angiotensin II-induced hypertensive cardiac disease. Hypertension. 2010;55:953-960.
15. Xing D, Hage FG, Chen YF, McCrory MA, Feng W, Skibinski GA, Majid-Hassan E, Oparil S, Szalai AJ. Exaggerated neointima formation in human C-reactive protein transgenic mice is IgG Fc receptor type I (Fc-RI)-dependent. Am J Pathol. 2008;172:22-30. (Pubitemid 351186364)
16. Hirschfield GM, Gallimore JR, Kahan MC, Hutchinson WL, Sabin CA, Benson GM, Dhillon AP, Tennent GA, Pepys MB. Transgenic human C-reactive protein is not proatherogenic in apolipoprotein E-deficient mice. Proc Natl Acad Sci USA. 2005;102:8309-8314. (Pubitemid 40800085)
17. Kovacs A, Tornvall P, Nilsson R, Tegnér J, Hamsten A, Björkegren J. Human C-reactive protein slows atherosclerosis development in a mouse model with human-like hypercholesterolemia. Proc Natl Acad Sci USA. 2007;104:13768-13773. (Pubitemid 350003395)
18. Teoh H, Quan A, Lovren F, Wang G, Tirgari S, Szmitko PE, Szalai AJ, Ward ME, Verma S. Impaired endothelial function in C-reactive protein overexpressing mice. Atherosclerosis. 2008;201:318-325.
19. Danenberg HD, Grad E, Swaminathan RV, Chen Z, Seifert P, Szalai AJ, Lotan C, Simon DI, Edelman ER. Neointimal formation is reduced after arterial injury in human crp transgenic mice. Atherosclerosis. 2008;201: 85-91.
20. Tennent GA, Hutchinson WL, Kahan MC, Hirschfield GM, Gallimore JR, Lewin J, Sabin CA, Dhillon AP, Pepys MB. Transgenic human CRP is not pro-atherogenic, pro-atherothrombotic or pro-inflammatory in apoE-/- mice. Atherosclerosis. 2008;196:248-255.
21. Torzewski J. C-reactive protein and atherogenesis: new insights from established animal models. Am J Pathol. 2005;167:923-925. (Pubitemid 41416245)
22. Reifenberg K, Lehr HA, Baskal D, Wiese E, Schaefer SC, Black S, Samols D, Torzewski M, Lackner KJ, Husmann M, Blettner M, Bhakdi S. Role of C-reactive protein in atherogenesis: can the apolipoprotein E knockout mouse provide the answer? Arterioscler Thromb Vasc Biol. 2005;25:1641-1646. (Pubitemid 41098934)
23. Verma S, Devaraj S, Jialal I. Is C-reactive protein an innocent bystander or proatherogenic culprit? C-reactive protein promotes atherothrombosis. Circulation. 2006;113:2135-2150.
24. Devaraj S, Singh U, Jialal I. The evolving role of C-reactive protein in atherothrombosis. Clin Chem. 2009;55:229-238.
25. Pepys MB, Hirschfield GM, Tennent GA, Gallimore JR, Kahan MC, Bellotti V, Hawkins PN, Myers RM, Smith MD, Polara A, Cobb AJ, Ley SV, Aquilina JA, Robinson CV, Sharif I, Gray GA, Sabin CA, Jenvey MC, Kolstoe SE, Thompson D, Wood SP. Targeting C-reactive protein for the treatment of cardiovascular disease. Nature. 2006;440:1217-1221.
26. Hein TW, Singh U, Vasquez-Vivar J, Devaraj S, Kuo L, Jialal I. Human C-reactive protein induces endothelial dysfunction and uncoupling of eNOS in vivo. Atherosclerosis. 2009;206:61-68.
27. D'Alessandris C, Lauro R, Presta I, Sesti G. C-reactive protein induces phosphorylation of insulin receptor substrate-1 on Ser307 and Ser612 in L6 myocytes, thereby impairing the insulin signalling pathway that promotes glucose transport. Diabetologia. 2007;50:840-849. (Pubitemid 46355815)
28. Verma S, Wang CH, Li SH, Dumont AS, Fedak PW, Badiwala MV, Dhillon B, Weisel RD, Li RK, Mickle DA, Stewart DJ. A self-fulfilling prophecy: C-reactive protein attenuates nitric oxide production and inhibits angiogenesis. Circulation. 2002;106:913-919. (Pubitemid 34925323)
29. Jialal I, Verma S, Devaraj S. Inhibition of endothelial nitric oxide synthase by C-reactive protein: clinical relevance. Clin Chem. 2009;55: 206-208.
30. Guan H, Wang P, Hui R, Edin ML, Darryl C, Zeldin DC, Wang DW. Adeno-associated virus-mediated human C-reactive protein gene delivery causes endothelial dysfunction and hypertension in rats. Clin Chem. 2009;55:274-284.
31. Vongpatanasin W, Thomas GD, Schwartz R, Cassis LA, Osborne-Lawrence S, Hahner L, Gibson LL, Black S, Samols D, Shaul PW. C-reactive protein causes downregulation of vascular angiotensin subtype 2 receptors and systolic hypertension in mice. Circulation. 2007;115: 1020-1028. (Pubitemid 46328296)